Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $13.6M | $8.09M | — | — | — |
| Revenue growth | — | — | — | — | — | — | -40.6% | — | — | — |
| Operating income | -$25.6M | -$54.9M | -$75.7M | -$119M | -$88.4M | -$72.3M | -$106M | -$104M | -$130M | -$179M |
| Operating margin | — | — | — | — | — | -530.5% | -1315.2% | — | — | — |
| Net income | -$23.8M | -$53.2M | -$74.8M | -$117M | -$88.3M | -$72.2M | -$86.0M | -$96.0M | -$125M | -$174M |
| Net margin | — | — | — | — | — | -530.0% | -1062.3% | — | — | — |
| EPS (diluted) | -$10.14 | -$2.88 | -$2.25 | -$2.91 | -$25.50 | -$10.14 | -$10.10 | -$4.83 | -$3.06 | -$1.99 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$20.1M | -$43.2M | -$70.2M | -$92.7M | -$56.6M | -$77.8M | -$98.0M | -$94.2M | -$100M | -$156M |
| Capital expenditures | $392K | $2.28M | $7.78M | $4.39M | $899K | $1.28M | $3.02M | $1.51M | $654K | $1.15M |
| Free cash flow | -$20.5M | -$45.5M | -$78.0M | -$97.1M | -$57.5M | -$79.0M | -$101M | -$95.7M | -$101M | -$157M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $7.68M | $52.1M | $86.4M | $76.0M | $155M | $119M | $155M | $74.0M | $80.2M | $59.9M |
| Total assets | — | $76.2M | $140M | $103M | $171M | $232M | $260M | $165M | $189M | $233M |
| Total liabilities | — | $11.3M | $14.4M | $23.4M | $39.1M | $24.2M | $48.6M | $38.5M | $51.4M | $52.5M |
| Shareholders' equity | -$37.9M | -$59.3M | $125M | $80.0M | $132M | $208M | $212M | $126M | $137M | $180M |
| Retained earnings | — | -$124M | -$199M | -$316M | -$405M | -$477M | -$563M | -$659M | -$783M | -$958M |
| Shares (wtd avg diluted) | — | — | 35.4M | 46.0M | 3.46M | 7.12M | 8.51M | 19.9M | 40.8M | 87.5M |
Every figure is extracted from Solid Biosciences Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.